Diabetes, Vol 39, Issue 1 76-82, Copyright © 1990 by American Diabetes Association

ARTICLES

Effects of converting-enzyme inhibition on barrier function in diabetic glomerulopathy

E Morelli, N Loon, T Meyer, W Peters and BD Myers
Department of Medicine, Stanford University School of Medicine, California.

Differential solute clearances were used to examine the effects of a 90-day course of enalapril on glomerular barrier function in 16 proteinuric patients with diabetic glomerulopathy. By day 90, plasma renin and prorenin became elevated, and arterial pressure declined. Transglomerular passage of dextrans of broad size distribution (radii 28-60 A) was lowered significantly. In a subset of 8 patients, withdrawal of enalapril was followed after an additional 30 days by a return of renin levels and arterial pressure to pretreatment levels. The dextran-sieving profile also returned to baseline, becoming uniformly elevated above treated day-90 levels. A theoretical analysis of the serial dextran-sieving profiles indicated that enalapril shifted glomerular pore size distribution to smaller size. These changes in barrier size selectivity were associated with a reduction in fractional albumin and IgG clearances during enalapril therapy and a subsequent rise in these quantities after its withdrawal; urinary protein excretion rate tended to vary in parallel. We conclude that inhibition of converting enzyme in humans with established diabetic glomerulopathy diminishes glomerular permeability to proteins by enhancing barrier size selectivity. Because neither enalapril therapy nor its withdrawal influenced the glomerular filtration or renal plasma flow rates significantly, we propose that the primary action of enalapril may be to modulate the intrinsic membrane properties of the glomerular barrier.
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				P. Ruggenenti, E. Perticucci, P. Cravedi, V. Gambara, M. Costantini, S. K. Sharma, A. Perna, and G. Remuzzi Role of Remission Clinics in the Longitudinal Treatment of CKD J. Am. Soc. Nephrol., June 1, 2008; 19(6): 1213 - 1224. [Full Text] [PDF]

				O. Deyneli, D. Yavuz, A. Velioglu, H. Cacma, N. Aksoy, G. Haklar, Y. Taga, and S. Akalm Effects of ACE Inhibition and Angiotensin II Receptor Blockade on Glomerular Basement Membrane Protein Excretion and Charge Selectivity in Type 2 Diabetic Patients Journal of Renin-Angiotensin-Aldosterone System, June 1, 2006; 7(2): 98 - 103. [Abstract] [PDF]

				R. Mathew, S. Futterweit, E. Valderrama, A. A. Tarectecan, J. E. Bylander, J. S. Bond, and H. Trachtman Meprin-{alpha} in chronic diabetic nephropathy: interaction with the renin-angiotensin axis Am J Physiol Renal Physiol, October 1, 2005; 289(4): F911 - F921. [Abstract] [Full Text] [PDF]

				J. Lea, T. Greene, L. Hebert, M. Lipkowitz, S. Massry, J. Middleton, S. G. Rostand, E. Miller, W. Smith, G. L. Bakris, et al. The Relationship Between Magnitude of Proteinuria Reduction and Risk of End-stage Renal Disease: Results of the African American Study of Kidney Disease and Hypertension Arch Intern Med, April 25, 2005; 165(8): 947 - 953. [Abstract] [Full Text] [PDF]

				T. Berl Angiotensin-Converting Enzyme Inhibitors versus AT1 Receptor Antagonist in Cardiovascular and Renal Protection: The case for AT1 Receptor Antagonist J. Am. Soc. Nephrol., January 1, 2004; 15(90010): S71 - 76. [Abstract] [Full Text]

				N. R. Loon Diabetic Kidney Disease: Preventing Dialysis and Transplantation Clin. Diabetes, April 1, 2003; 21(2): 55 - 62. [Abstract] [Full Text] [PDF]

				G. Viberti, N. M. Wheeldon, and for the MicroAlbuminuria Reduction With VALsartan Microalbuminuria Reduction With Valsartan in Patients With Type 2 Diabetes Mellitus: A Blood Pressure-Independent Effect Circulation, August 6, 2002; 106(6): 672 - 678. [Abstract] [Full Text] [PDF]

				G. L. Bakris A Practical Approach to Achieving Recommended Blood Pressure Goals in Diabetic Patients Arch Intern Med, December 10, 2001; 161(22): 2661 - 2667. [Abstract] [Full Text] [PDF]

				B. Fabris, R. Candido, M. Carraro, F. Fior, M. Artero, C. Zennaro, M. R. Cattin, A. Fiorotto, M. Bortoletto, C. Millevoi, et al. Modulation of Incipient Glomerular Lesions in Experimental Diabetic Nephropathy by Hypotensive and Subhypotensive Dosages of an ACE Inhibitor Diabetes, November 1, 2001; 50(11): 2619 - 2624. [Abstract] [Full Text] [PDF]

				D. MACCONI, M. GHILARDI, M. E. BONASSI, E. I. MOHAMED, M. ABBATE, F. COLOMBI, G. REMUZZI, and A. REMUZZI Effect of Angiotensin-Converting Enzyme Inhibition on Glomerular Basement Membrane Permeability and Distribution of Zonula Occludens-1 in MWF Rats J. Am. Soc. Nephrol., March 1, 2000; 11(3): 477 - 489. [Abstract] [Full Text] [PDF]

				A. Remuzzi, N. Perico, F. Sangalli, G. Vendramin, M. Moriggi, P. Ruggenenti, and G. Remuzzi ACE inhibition and ANG II receptor blockade improve glomerular size-selectivity in IgA nephropathy Am J Physiol Renal Physiol, March 1, 1999; 276(3): F457 - F466. [Abstract] [Full Text] [PDF]

				C. PUPILLI, L. LASAGNI, P. ROMAGNANI, F. BELLINI, M. MANNELLI, N. MISCIGLIA, C. MAVILIA, U. VELLEI, D. VILLARI, and M. SERIO Angiotensin II Stimulates the Synthesis and Secretion of Vascular Permeability Factor/Vascular Endothelial Growth Factor in Human Mesangial Cells J. Am. Soc. Nephrol., February 1, 1999; 10(2): 245 - 255. [Abstract] [Full Text]

				G. Remuzzi and P. Ruggenenti Slowing the Progression of Diabetic Nephropathy N. Engl. J. Med., November 11, 1993; 329(20): 1496 - 1497. [Full Text]